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Lysosomal free sialic acid–storage diseases include the allelic disorders Salla disease (SD) and infantile sialic
acid–storage disease (ISSD). The defective gene, SLC17A5, coding for the lysosomal free sialic acid transporter was
recently isolated by positional cloning. In the present study, we have identified a large number of mutations in
SLC17A5 in patients presenting with either Salla disease or the ISSD phenotype. We also report for the first time
the exon-intron boundaries of SLC17A5. All Finnish patients with SD ( ) had a missense mutation changingnp 80
a highly conserved arginine to cysteine (R39C); 91% of them were homozygotes for this old founder mutation.
The compound-heterozygote patients, with the founder mutation in only one allele, presented with a more severe
phenotype than did the homozygote patients. The same R39C mutation was also found both in most of the Swedish
patients with SD and in a heterozygous form in five patients from central Europe who presented with an unusually
severe (intermediate) SD phenotype. Ten different mutations, including deletions, insertions, and missense and
nonsense mutations, were identified in patients with the most severe ISSD phenotype, most of whom were compound
heterozygotes. Our results indicate some genotype-phenotype correlation in free sialic acid–storage diseases, sug-
gesting that the phenotype associated with the homozygote R39C mutation is milder than that associated with
other mutations.
Introduction
Lysosomal free sialic acid–storage diseases (SASD [MIM
269920]) include the allelic disorders Salla disease (SD),
enriched in the Finnish population, and infantile sialic
acid–storage disease (ISSD [Aula and Gahl, in press]).
The clinical symptoms of SD consist of moderate to se-
vere psychomotor retardation and ataxia presenting usu-
ally at age !1 year. The progression of symptoms in SD
is slow; the oldest patient died at age 72 years. The
clinical picture of ISSD is much more severe. The affected
newborns exhibit dysmorphic features, an enlarged liver
and spleen, and a failure to thrive immediately after
birth. These patients have a shortened life span, usually
!2 years. Progressive cerebellar atrophy and dysmyeli-
nation have been documented by magnetic-resonance
imaging in patients with SD (Haataja et al. 1994; Varho
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et al. 1999). In addition to the main phenotypes of SD
and ISSD, rare intermediate phenotypes have also been
reported (Fois et al. 1987; Schleutker et al. 1995b).
As a result of defective egress of free sialic acid from
lysosomes, patients with SD excrete large amounts of
free sialic acid in their urine and store it excessively, at
10–30 times the normal rates, in several types of tissues
and cultured fibroblasts (Renlund et al. 1986; Mancini
et al. 1989). In patients with ISSD, the urinary excretion
and intracellular storage is even higher, up to 100 times
the normal rate. Electron-microscopic and histochemi-
cal studies have shown that excessive sialic acid accu-
mulates in the lysosomes (Aula et al. 1979). We have
recently identified the gene, SLC17A5, responsible for
the lysosomal-membrane sialic acid transport and have
found mutations in Finnish patients with either SD or
ISSD (Verheijen et al. 1999). The gene is located on
chromosome 6q and has an open reading frame (ORF)
of 1485 bp. It encodes sialin, a protein of 495 amino
acids, which is predicted to be an integral lysosomal
membrane protein with 12 transmembrane (TM) do-
mains. In the present study, we analyzed, for mutations
in the SLC17A5 gene, a total of 100 Finnish and non-
Finnish patients with SD and 10 patients with ISSD.
We initially screened the patients’ DNA for the identified
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Table 1
Patients and Summary of Clinical Findings in SASD
Disease Clinical Characterization Age at Onset
Free Sialic Acid
in Urinea No. of Cases in Study
SD Hypotonia and ataxia, ocular squint, delayed
development, few words, able to walk; IQ 20–30;
life span near normal
6–12 mo 12 fold (5–36) 73 Finnish,
15 Swedish,b
2 Englishc
Intermediate
“severe Salla”
Severe hypotonia, later ataxia, spasticity; growth
delay; no organomegaly; seizures; shortened
life span
1–6 mo 15–34 fold 7 Finnish, 1 Dutch,d
1 Italian,e 1 Ger-
manb
ISSD Intrauterine hydrops, neonatal ascites, enlarged liver;
dysmorphic features; failure to thrive; early death
(age !2 years)
Intrauterine 102 fold (18–245) 10 Whitef
a Mean of free sialic acid in normal controls: nM/mg creatinine (Aula and Gahl, in press).58 19
b Reported by Schleutker et al. (1995b).
c Reported by Robinson et al. (1997).
d Reported by Mancini et al. (1992).
e Reported by Fois et al. (1987).
f Patients Mc.I., J.G., R.D., D.R., A.Z., and A.B. (Verheijen et al. 1999), S.L., C.J., and C.G. (Schleutker et al. 1995b), and P.M. (Dr. I.
Maire, Lyon).
Finnish mutation (R39C) and then sequenced the entire
coding region and the exon-intron boundaries in those
patients who did not have the Finnish founder mutation,
SallaFIN, in both alleles. A wide spectrum of different
DNA alterations was identified in disease alleles. The
characterization of mutations in SLC17A5, when com-
pared with the clinical findings, suggests a correlation
between the molecular defect and the phenotype of the
patients.
Patients and Methods
Patients and Clinical Summary
A clinical summary of the sialic acid–storage disorders
is presented in table 1. All diagnoses were based on
typical clinical findings, histology, and biochemical as-
says of sialic acid. Most of the Finnish patients with SD
( ) presented the classical form of the disease. Onnp 73
a clinical basis, seven patients (K.N., L.J., I.P., K.M.,
M.M., L.Mt., and L.Mo.) had a more severe type of SD.
The onset of symptoms was earlier than that in typical
SD; the patients were spastic, were unable to walk, and
had seizures and severe growth retardation. The free
sialic acid levels in their urine were slightly higher than
those in typical patients with SD. The first signs of the
disease were detected at age !6 mo.
The clinical findings and course of the disease were,
for Swedish patients ( ), all compatible with thenp 15
findings in the Finnish patients with SD. Also, two pa-
tients in one British family (Le.C. and Le.L.) had the
Finnish type of the disease. Three patients—one Italian
(P.E.), one Dutch (B.E.), and one German (G.A.)—had
a severe form of SD, the intermediate type, according to
the clinical data. Ten patients—four British (C.G., C.J.,
Mc.I., and S.L.), one Italian (A.B.), one Yugoslavian
(A.Z.), two French (P.M. and D.R.), and two French-
Canadian (J.G. and R.D.)—were classified as having the
severe, early-onset, fatal ISSD.
Allele-Specific PCR to Detect the Finnish Mutation
We performed allele-specific PCR (Wu et al. 1989)
using either 5′-CAGTGTGCTGCTCTGCTC-3′ (wild
type) or 5′-CAGTGTGCTGCTCTGCTT-3′ (mutant) as
a 5′ primer and 5′-AGGCCAAAATTGCTAAGTTGT-3′
as a 3′ primer. Cycling conditions were 11 min at 95C,
30 s at 95C, 30 s at 57C, and 1 min at 72C, for 35
cycles, with thermal cycler PTC-225 (MJ Research) and
AmpliTaq Gold (Roche).
cDNA Sequencing
Fibroblast cell lines were established from patients
with either SD or ISSD who have been described else-
where. Fibroblasts were cultured in DMEM (Gibco BRL,
Life Technologies) supplemented with 10% fetal calf se-
rum and antibiotics. Total RNA was isolated from fi-
broblasts by use of the RNeasy Midi Kit (Qiagen),
according to the manufacturer’s instructions. The first-
strand cDNA was subsequently generated by a standard
protocol using AMV-RT enzyme (NEB). cDNA was am-
plified by PCR with a PTC-225 thermal cycler (MJ Re-
search) and Dynazyme (Finnzymes), under the appro-
priate conditions. PCR products were analyzed on 1%
agarose gel and subsequently were sequenced using the
ABI Prism Big Dye Terminator Cycle Sequencing kit (Ap-
plied Biosystems) and an ABI 377 (Applied Biosystems)
fluorescent sequencer. We sequenced the complete ORF,
using four different primer pairs: P1, forward 5′-
GTGGCGAGTACACCTGCTCA-3′ and reverse 5′-CT-
TCTAGTGCTCTGAGTACAA-3′; P2, forward 5′-TGG-
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Table 2
Primers for Amplification and Sequencing of SLC17A5 Exons
Exon and PCR and Sequencing Primers
Amplified
Product
(bp)
Annealing
Temperature
(C)
2:
Forward, 5′-AGGAGTTCAAGACCAGCCTAAGCAACATG-3′ 370 54
Reverse, 5′-TACACAAACAAAGTATAGTTTCTGTAGGATGA-3′
3:
Forward, 5′-AATCTCATTTATATGTACTTACATGCCAGT-3′ 415 53
Reverse, 5′-GGTTCATATTCATACCAAAGAATGACATC-3′
4:
Forward, 5′-CATGGAACCTGATTCGTTTGATTCTTATC-3′ 310 58
Reverse, 5′-AACATTGCATCGTTCTGGTATGCAGGCC-3′
5:
Forward, 5′-CCCATCCTCTGTAAGCAGTAGACTTGTC-3′ 300 58
Reverse, 5′-CAGGAAGTGTTTCAGAACTGTGGTTCAG-3′
6:
Forward, 5′-TCAAGACATGTAAAAATTGTTGTTGGTGC-3′ 345 54
Reverse, 5′-CTACTTTGTCTAGAGCATGCACAATAGG-3′
7:
Forward, 5′-GAATTCTGGATAGAGTTTTAGCTGATACC-3′ 420 53
Reverse, 5′-AGGACAGCAGAGTAAAATGGAAGATACAG-3′
8:
Forward, 5′-TTCAAGTGGTGGTCATTGGCTGTGATGA-3′ 345 58
Reverse, 5′-GTGATTAGAGCGAGGTGTTCTGTGTTGAG-3′
9:
Forward, 5′-GTCTTCCAGGCAATATAGTGTTTCTACAG-3′ 390 56
Reverse, 5′-AAGTGCTGGGATTACAGGTGTGAGTCACC-3′
10:
Forward, 5′AGGCTGCAGTGAGCTGAGATCATCCCAC-3′ 380 55
Reverse, 5′-ATACTTTCCCATCCATTAAGGCATTTAGC-3′
11:
Forward, 5′-ATGTGGCTGTTTTAACACTCTTGTGACAC-3′ 330 64
Reverse, 5′-ATAGAATGCTTACACAATACAGAAGGCAC-3′
AGGATATGTTGCCAGCA-3′ and reverse 5′-GTGTG-
CAACTACGATAGCCC-3′; P3, forward 5′-ATCAGC-
TTTCTTCACAGAAGTCA-3′ and reverse 5′-CAATAT-
CCAGATGGTTGATGC-3′; and P4, forward 5′-GTA-
GCTGCTGGCTTCATTGG-3′ and reverse 5′-ATACA-
TTAATAGAGGCAGGATTA-3′.
Genomic DNA Sequencing
We amplified exons 2–11 from genomic DNA, using
intronic primers flanking the exons, as shown in table
2. All specific primer sets were designed in the intronic
sequences flanking each exon, at a distance of 40 bp
from the exon-intron boundary. The PCR reactions were
carried out in a final volume of 50 ml in a standard
reaction condition, with Dynazyme DNA polymerase
(Finnzymes). Exons were amplified for 30–35 cycles at
either 94C for 1 min or 53C–64C (depending on the
primer pair) for 1 min and 72C for 1 min, followed by
a 10-min extension step at 72C. PCR products were
visualized on 1% agarose gel and subsequently were
sequenced using an ABI 377 fluorescent sequencer (Ap-
plied Biosystems).
Northern Hybridization
Total RNAs were extracted from respective fibroblast
cultures, with a Qiagen RNeasy Midi Kit used according
to the manufacturer’s protocol. An RNA filter was made
using standard protocols. A 32P-labeled 140-bp PCR
fragment amplified from SLC17A5 cDNA was used in
the hybridization, which was performed at 68C for 1
h with ExpressHyb solution (Clontech Laboratories).
The filter was washed as recommended by the manu-
facturer. To evaluate the loading of the samples, the filter
was subsequently rehybridized with 32P-labeled b-actin
(Clontech).
Genomic Structure of SLC17A5
We searched the human genome database for genomic
clones, using the BLASTN algorithm (Altschul et al.
1990) and the SLC17A5 cDNA sequence. We found one
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Table 3
Sequence of the Exon-Intron Boundaries of the SLC17A5 Gene
Exon Positions 5′ Splice Donor 3′ Splice Acceptor
1 94 GGGCCGAAGCCG-gtaagcggcggg caatctttatttcag-CTCCAGTGTGC
2 95–291 CATAATCAAACG-gtaggtgctatt ttctgatttttgtag-GGTAAGAAGTAC
3 292–525 GGACTAGGAGAG-gtaattttcttt gttcccttctctcag-GGTGTTACATTT
4 526–613 TTTCATATGCAG-gtgagataacaa tatgtgttgttctag-GAGCACAGCTTG
5 614–700 TCTACTTTTTTG-gtaagtttaaaa ttctattttaag-GTACTATTGGAATA
6 701–819 TTAAGAAATCAG-gtatggactttg tgcctggttcttcag-CTTTCTTCACAG
7 820–978 AATGTTCAAGAG-gtaagaaaaaat tcttattccttccag-AATGGGTTTTTA
8 979–1111 TAGCCTTATAG-gtaagtgaagcaa ctttttaactccag-GAATGATTGGGA
9 1112–1259 TATTGCTCCTTC-gtgagtactaat aaaatgtttctacag-GTATGCTGGTAT
10 1260–1350 CTGACCCCTGAT-gtaagtagataa tgtcttcctttatag-AACACTGTTGGA
11 1351
Homo sapiens clone (HSJ397H23) that contained 22
unordered pieces of genomic DNA covering the
SLC17A5 cDNA. This sequence was not finished and
could contain errors. We assembled the right order of
the pieces and their orientation. This sequence contained
10 complete exons, covering most of the ORF of
SLC17A5. The missing 5′ exon was determined by se-
quencing a genomic clone (PAC 202M22) covering the
SLC17A5 gene. We chose as the sequencing primer a
sequence derived from the next intron. Intron primers
flanking all intron-exon boundaries were chosen (table
3), and all exons were amplified by PCR using genomic
DNA isolated from cultured human fibroblasts. All am-
plified exons and boundaries were sequenced using an
Applied Biosystems ABI 377 fluorescent sequencer. Us-
ing this approach, we determined all 11 exons covering
the whole ORF. Exon 11 covered also the 3′ UTR. Be-
cause of the missing 5′ sequence, the exact length of exon
1 could not be determined. For genomic amplification
of the first exon, an exon 1 primer was used together
with a reverse primer from the intron boundary of the
first intron: forward, 5′-CGGCATGCGTAGACCGA-
CG-3′; reverse, 5′-CTCGCGCCTGAGCAGCTC-3′.
Results
SallaFIN
Allele-specific PCR was used to monitor for the
115CrT mutation in the leukocyte DNA from 80 Finn-
ish patients with SD. Altogether, 73 patients proved to
be homozygous for this nucleotide change. The mutation
changes a highly conserved arginine (R39) into cysteine,
leading to an alteration just before the first TM domain
of the predicted polypeptide chain (fig. 1A). Seven pa-
tients were found to be compound heterozygotes, having
the SallaFIN mutation in only one allele and another mu-
tation in the other allele. Thus, the SallaFIN mutation was
found in 95% of Finnish SD chromosomes, indicating,
again, a founder effect in the Finnish population, a find-
ing that is characteristic to diseases belonging to the
Finnish disease heritage (Peltonen et al. 1999). Of 15
Swedish patients with SD, 12 were homozygous for the
SallaFIN mutation, 2 were heterozygous, and 1 did not
have this mutation in either allele. Somewhat surpris-
ingly, we found the SallaFIN mutation in a heterozygous
form in five non-Scandinavian patients with SD. These
patients are of British, Dutch, Italian, and German origin
and have no known relationship to Finland, nor are they
known to be related to each other (table 4).
Carrier Frequency
In 226 control DNA samples from all regions of Fin-
land, we applied allele-specific PCR to screen for the
R39C mutation and found one carrier. This suggests a
populationwide carrier frequency of ∼1/200. We also
screened for this mutation in a study sample of 107
individuals originating from the northeastern region of
Finland, where SD is known to be more prevalent. Two
carriers were identified, suggesting a higher regional fre-
quency of the disease allele, ∼1%, which is well in ac-
cordance with previous estimates (Aula et al. 1986).
Mutations in Finnish Compound-Heterozygote Patients
with SD
To identify the mutations in the other alleles of the
Finnish compound-heterozygote patients with SD, we
first sequenced the coding region, using, as a template,
reverse-transcribed RNA from patients’ fibroblasts. Two
patients (K.N. and L.J.) were found to share a 294-bp
(nucleotide positions 526–819) deletion in their other
allele. This deletion is predicted to result in an in-frame
deletion of 98 amino acids (fig. 1A). The deleted region
encompasses exons 4–6, also including the same five
amino acids (SSLRN) deleted in six severely affected pa-
tients with ISSD (see below). One patient (I.P.) had a
missense mutation, 406GrA, in the other allele, which
changes a lysine into glutamic acid (K136E) in the cy-
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Figure 1 A, Sialin mutations in patients with free SASD shown
in the predicted model of sialin in the lysosomal membrane are denoted
in terms of amino acid position. Only the start points of deletions and
insertions are indicated. SSLRN p in-frame deletion of Ser, Ser, Leu,
Arg, and Asn. B, SLC17A5 mutations in patients with free SASD.
Point mutations are marked with an arrow (f), deletion points with
an upside-down triangle (), and insertion points with a triangle ().
tosolic loop just before the third TM domain. In five
patients (K.M., L.Mt., L.Mo., M.M., and V.A.), cDNA
sequencing did not reveal the mutation of the other al-
lele. In these cases, we sequenced genomic DNA, in-
cluding the exon-intron boundaries and part of the in-
trons, to identify all disease mutations. We were able to
find the second mutation in three additional Finnish pa-
tients (table 5). Two sisters (L.Mt. and L.Mo.) and one
other patient (M.M.) have a 2-bp deletion (1007–
1008del) in exon 8. This results in a frameshift and,
consequently, in the formation of 13 novel amino acids
followed by a premature stop codon. In total, we iden-
tified three different mutations, in addition to SallaFIN,
in Finnish patients with SD. In two compound-hetero-
zygote cases, the mutation of the other allele remains
unknown.
Mutations in Non-Finnish Compound-Heterozygote
Patients with SD
The mutations in the other alleles of the two Swedish
heterozygotes could not be detected in their fibroblast
cDNA. By genomic sequencing, we identified two novel
mutations (table 5). One patient (J.T.) was found to have
a nonsense mutation (309GrA) in exon 3, predicted to
result in only a short (102 amino acids) translation prod-
uct from this allele. In the other patient (A.S.), we iden-
tified also a nonsense mutation (719GrA) in exon 6.
An intronic mutation (∼951GrC) was found in one
patient (K.H.) who does not have the R39C mutation
in either allele. This nucleotide substitution occurs one
base upstream of the first base of exon 2 and, conse-
quently, results in exon skipping, since cDNA sequencing
revealed a deletion of 197 bp covering the whole of exon
2. The other allele of this patient carried the same 2-bp
deletion (1007–1008del) as was seen in three Finnish
compound heterozygotes.
As mentioned above, five foreign patients were found,
on the basis of allele-specific PCR results, to carry the
SallaFIN mutation resulting in R39C substitution in one
allele. No mutations in the other allele could be estab-
lished by cDNA sequencing. The sequencing of genomic
DNA revealed the mutation in the other allele in the
German patient (G.A.), who had a genomic deletion en-
compassing exons 3 and 4. The English sisters were
found to have a 2-bp deletion (1138–1139del2bp) that
results in a frameshift and a premature stop codon. The
mutation of the other allele in the Dutch (B.E.) and in
the Italian (P.E.) patients has yet to be identified. Alto-
gether, we identified five novel mutations in the non-
Finnish compound-heterozygote patients with SD.
Mutations in Patients with ISSD
None of the patients with ISSD had the SallaFIN mu-
tation. Using the initial cDNA and further genomic DNA
sequencing, we were able to find 10 different mutations,
including missense mutations, deletions, and insertions
(table 4). Surprisingly, we found an identical 15-bp de-
letion (802–816del15bp) in six seemingly unrelated pa-
tients(C.G., C.J., J.G., Mc.I., R.D., and S.L.) of Cana-
dian, English, and French origin. One of these patients
(S.L.) is a child of consanguineous parents and is ho-
mozygous for the mutation, whereas all the others are
heterozygotes. This mutation is predicted to lead to a
deletion of five amino acids (SSLRN) in the cytosolic
loop between TM domains 6 and 7. The mutation in
the other allele of these heterozygotes has been identified
in two patients. In one case (Mc.I.), a 2-bp insertion
(1355–1356ins2bp) in exon 11 was found. This causes
a frameshift and is predicted to lead to formation of
novel amino acids and to read through of the normally
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Table 4
Mutations in Non-Scandinavian Patients with SASD
PHENOTYPE
ALLELE 1 ALLELE 2
Nucleotide
Change
Predicted
Polypeptide
Consequence
Nucleotide
Change
Predicted
Polypeptide
Consequence
Severe SD (intermediate):
Le.L. 115CrT R39C 1138–1139del a Frameshift, 7 novel amino acids, pre-
mature stop
Le.C. 115CrT R39C 1138–1139del a Frameshift, 7 novel amino acids, pre-
mature stop
G.A. 115CrT R39C 292–611del a Deletion of exons 3 and 4
B.E. 115CrT R39C ? ?
P.E. 115CrT R39C ? ?
ISSD:
S.L. 802–816del In-frame deletion of 5
amino acids in the
cytosolic loop be-
tween TM domains 6
and 7
802–816del In-frame deletion of 5 amino acids in
the cytosolic loop between TM do-
mains 6 and 7
C.J. 802–816del In-frame deletion of 5
amino acids in the
cytosolic loop be-
tween TM domains 6
and 7
1112GrT a G371V
Mc.I.b 802–816del In-frame deletion of 5
amino acids in the
cytosolic loop be-
tween TM domains 6
and 7
1355–1356insAAa Frameshift, read-through of stop codon
J.G.b 802–816del In-frame deletion of 5
amino acids in the
cytosolic loop be-
tween TM domains 6
and 7
? ?
R.D.b 802–816del In-frame deletion of 5
amino acids in the
cytosolic loop be-
tween TM domains 6
and 7
? ?
C.G. 802–816del In-frame deletion of 5
amino acids in the
cytosolic loop be-
tween TM domains 6
and 7
? ?
P.M. 526delG 37 novel amino acids,
premature stop
918TrGa Y306X
D.R.b 533delC Frameshift, 33 novel
amino acids, prema-
ture stop
1112–1259del Deletion of exon 9
A.Z.b 548ArG H183R 1001CrG P334R
A.B.b 978–979ins500bp Premature stop 978–979ins500bp Premature stop
a Mutation not detectable in cDNA.
b Reported by Verheijen et al. (1999).
used stop codon. Another patient (C.J.) had a missense
mutation (1112GrT) of the first base of exon 9, chang-
ing a conserved glycine into valine. One French patient
(P.M.) was shown to have a heterozygous 1-bp deletion
(526delG) that results in a frameshift—formation of
37 novel amino acids followed by a premature stop.
In the other allele, a nonsense mutation (918TrG) was
found in exon 7. A homozygous 500-bp insertion
(978ins500bp) leading to a truncated polypeptide was
found in an Italian patient, and two different missense
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Figure 2 Expression of SLC17A5 in patients with classical SD,
severe SD, and ISSD. A northern blot made from total RNAs was
hybridized with a 32P-labeled 140-bp PCR probe amplified from
SLC17A5 cDNA and subsequently rehybridized with 32P-labeled b-
actin, to evaluate the loading of the samples.
Table 5
Mutations in the Scandinavian Patients with SD
PHENOTYPE
ALLELE 1 ALLELE 2
Nucleotide
Change
Predicted
Polypeptide
Consequence
Nucleotide
Change
Predicted
Polypeptide
Consequence
Classical SD:
Swedish (n p 12) 115CrT R39C 115CrT R39C
Finnish (n p 73) 115CrT R39C 115CrT R39C
V.A. 115CrT R39C ? ?
Severe SD (intermediate):
Finnish:
K.N. 115CrT R39C 526–819del Deletion of exons
4–6
L.J. 115CrT R39C 526–819del Deletion of exons
4–6
I.P. 115CrT R39C 406ArG K136E
K.M. 115CrT R39C ? ?
M.M. 115CrT R39C 1007–1008dela 13 Novel amino
acids, prema-
ture stop
L.mt. 115CrT R39C 1007–1008dela 13 Novel amino
acids, prema-
ture stop
L.mo. 115CrT R39C 1007–1008dela 13 Novel amino
acids, prema-
ture stop
Swedish:
K.H. 95–291del, 197 bp
(cDNA), ∼951GrC
(genDNA)a
Removes splice site, deletion of exon 2 1007–1008dela 13 Novel amino
acids, prema-
ture stop
J.T. 115CrT R39C 309GrAa W103X
A.S. 115CrT R39C 719GrAa W240X
a Mutation not detectable in cDNA.
mutations (H183R and P334R) were detected in a Yu-
goslavian patient. Altogether, we have identified 10 dif-
ferent mutations in our study sample of 10 patients with
ISSD.
Northern Analysis
We hybridized a SLC17A5-specific cDNA probe to a
northern filter with total RNA from patients and one
control. Steady-state mRNA from fibroblasts of two
classical, R39C-homozygote, and three severely affected
compound-heterozygote patients with SD (K.N., R39C/
526–819del; L.Mt., R39C/1007–1008del; and I.P.,
R39C/406ArG), as well as from two patients with ISSD
(S.L., 802–816del/802–816del; and Mc.I., 802–816del/
1355–1356ins) were analyzed. On the basis of the mu-
tations in these patients, we anticipated a difference in
the expression levels of SLC17A5 RNA but could not
detect significant differences, in the steady-state mRNA
levels, between the patients and the control (fig. 2).
Discussion
We analyzed all known Finnish patients with SD and
found the same missense mutation (115CrT/R39C) in
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95% of all disease chromosomes. This missense muta-
tion, SallaFIN, which changes an arginine into cysteine,
is clearly a founder mutation that, because of the pop-
ulation history and geographic isolation of Finland, en-
riched in the Finnish population (Nevanlinna 1972). The
presence of a founder mutation already had been antic-
ipated, on the basis of haplotype analyses that revealed
a common haplotype in 95% of the disease chromo-
somes in a 60-kb area flanking the disease locus (Schleut-
ker et al. 1995b). Our results regarding SD are in line
with the results of earlier observations of several other
monogenic disorders in Finland. One major founder mu-
tation has been established systematically for all the dis-
eases belonging to the Finnish disease heritage (Peltonen
1997; Peltonen et al. 1999).
We investigated the carrier frequency of the SallaFIN
mutation in Finland—both nationwide and in the north-
eastern region—where there is a higher prevalence of
the disease. The results show that the estimated carrier
frequency is four times higher in the Salla-Kuusamo area
(1.87%), compared with that in the overall population
(0.44%). This is well in accordance with previous es-
timates based on prevalence of the disease (Aula et al.
1986).
Finding the SallaFIN in Swedish families with SD that
are not known to be related to Finnish pedigrees is not
surprising in light of the admixture of these populations
during the centuries in which they shared a common
history. However, the presence of the SallaFIN mutation
in central and southern European families is unexpected
and provides interesting speculations about the age, or-
igin, and migration of this disease mutation. On the
basis of the long genetic interval (10 cM) with signifi-
cant linkage disequilibrium, the SallaFIN mutation can
be concluded to have been introduced into the Finnish
population relatively recently (∼20 generations ago
[Schleutker et al. 1995a]). Where this mutation origi-
nally came from is not known, but its presence in central
and southern European SD alleles suggests that this mu-
tation arrived in Finland with immigrants from Europe.
One major founder mutation covering 95% of dis-
ease alleles provides excellent diagnostic possibilities
in Finland. A simple gene test for the R39C mutation
has been developed using minisequencing technology
(Syvanen et al. 1992), and this test can also be used
for carrier detection and prenatal diagnosis of SD.
Even carrier screening in selected populations may
become feasible, either for the SD mutation alone or
in combination with other prevalent mutations in the
population.
The mutations identified in the SLC17A5 gene show
a wide spectrum of disease-causing DNA variations. We
identified missense and nonsense mutations, splice-site
mutations, and insertions and deletions. On the basis
of the distribution of the mutations, no mutational hot-
spot was suggested, although some clustering of mu-
tations is seen in exons 4 and 8 (fig. 1B). Some of the
nonsense mutations can be predicted to result in a short
polypeptide product from this allele, whereas some de-
letions result in the formation of a few novel amino
acids and a longer but, most probably, nonfunctional
protein product. In northern analyses, we could not de-
tect any differences in the total steady-state mRNA lev-
els between patients with classical SD (R39C homo-
zygotes), those with the severe form of SD (compound
heterozygotes), and those with ISSD (fig. 2). However,
8 of 19 mutations could not be identified in the cDNA
produced from the mRNA of these cell lines, suggesting
a significantly lower steady-state transcript level for
these mutant alleles. These alleles represented nonsense
mutations, deletions, and an insertion.
The phenotypic variation seen in SD seems, to some
extent, to correlate with the presence of the R39C mu-
tation. All those patients with SD who are homozygous
for the SallaFIN mutation can be classified as having the
classical, slowly progressing SD phenotype. They show
the typical symptoms of SD: early-onset psychomotor
retardation and ataxia, hypotonia, and elevated excre-
tion of free sialic acid in their urine (up to 30 times the
normal values; table 1). With one exception (V.A.), the
compound-heterozygote patients are more severely af-
fected than are the R39C homozygotes. The amount of
free sialic acid in urine is usually higher in the hetero-
zygotes than in the homozygotes (table 1), and their
phenotype is more severe. Interestingly, the non-Finnish
patients who have the SallaFIN mutation also have a
milder phenotype than do those who have altogether
different mutations. Many compound-heterozygote pa-
tients have been classified as having the phenotype in-
termediate between the classical SD and ISSD pheno-
types (Schleutker et al. 1995b). The most severe
phenotype of the disease, ISSD, is found in individuals
in whom neither of the mutated alleles carries the
SallaFIN mutation. The presence of the R39C mutation
in the sialin polypeptide thus seems to preserve more of
the protein’s normal function, compared with other mu-
tations found in compound-heterozygote patients. If the
lysosomal sialic acid transporter, like several membrane-
transporter proteins, functions as a multimer on the
lysosomal membrane, the R39C mutation does not seem
to greatly disturb either the primary folding or the po-
tential multimerization of the protein. The other mu-
tations may distort the secondary structure of the pro-
tein and hinder the membrane targeting or the
formation of an active dimer or multimer. Although
some mutant alleles seem to result in very low transcript
levels, interference of the polypeptides is suggested, on
the basis of the more severe clinical phenotype of the
majority of compound-heterozygote patients with the
SallaFIN mutation in their other allele. Our ongoing stud-
840 Am. J. Hum. Genet. 67:832–840, 2000
ies of the expression of the normal and mutant
SLC17A5 alleles will shed further light on the structure
and function of the sialin protein.
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